Adamas Pharmaceuticals (ADMS) Downgraded by BidaskClub to “Hold”

Adamas Pharmaceuticals (NASDAQ:ADMS) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a report released on Saturday.

A number of other equities analysts also recently weighed in on the stock. ValuEngine raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. Mizuho reissued a “buy” rating and issued a $48.00 price target on shares of Adamas Pharmaceuticals in a report on Tuesday, January 23rd. Zacks Investment Research downgraded shares of Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Piper Jaffray Companies set a $52.00 price target on shares of Adamas Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, December 19th. Finally, Cowen set a $55.00 price target on shares of Adamas Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, December 13th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $44.86.

Adamas Pharmaceuticals (NASDAQ ADMS) traded down $2.48 during midday trading on Friday, hitting $35.96. 1,010,000 shares of the stock traded hands, compared to its average volume of 827,615. Adamas Pharmaceuticals has a 12-month low of $13.50 and a 12-month high of $44.00. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.32 and a current ratio of 8.35. The company has a market cap of $766.28, a price-to-earnings ratio of -10.70 and a beta of 1.17.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.01) by ($0.03). The company’s revenue was down 99.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.66) EPS. equities analysts forecast that Adamas Pharmaceuticals will post -3.84 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC purchased a new stake in shares of Adamas Pharmaceuticals in the second quarter worth about $606,000. JPMorgan Chase & Co. lifted its holdings in shares of Adamas Pharmaceuticals by 13,028.4% in the third quarter. JPMorgan Chase & Co. now owns 136,273 shares of the specialty pharmaceutical company’s stock worth $2,839,000 after buying an additional 135,235 shares in the last quarter. Hikari Power Ltd purchased a new stake in shares of Adamas Pharmaceuticals in the third quarter worth about $635,000. EAM Investors LLC purchased a new stake in shares of Adamas Pharmaceuticals in the third quarter worth about $1,795,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Adamas Pharmaceuticals by 4.0% in the second quarter. Vanguard Group Inc. now owns 745,237 shares of the specialty pharmaceutical company’s stock worth $13,034,000 after buying an additional 28,818 shares in the last quarter. 78.31% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Adamas Pharmaceuticals (ADMS) Downgraded by BidaskClub to “Hold”” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/02/03/adamas-pharmaceuticals-adms-downgraded-by-bidaskclub-to-hold-2.html.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply